Amicrobe Selects Clinical Formulation for Amicidin-α PFC, Supported by Department of Defense for Prolonged Field Care of Injure Warfighters

CARLSBAD, CA. May 10, 2022 -- Amicrobe, Inc. develops synthetic biologics with physical and antimicrobial properties, called Amicidins. Today, the Company announced the selection of lead clinical formulation for Amicidin-α PFC (Prolonged Field Care), a key milestone in the development of a new product for military field care of injured warfighters. The full press release can be viewed here.

​